Kasper Philipp, Göbel Heike, Michels Guido
Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Köln.
Institut für Pathologie, Universitätsklinikum Köln.
Dtsch Med Wochenschr. 2020 Feb;145(3):189-194. doi: 10.1055/a-1008-7206. Epub 2020 Feb 4.
A 72-year-old heart transplant recipient presented to the hospital with progressive dyspnea. His immunosuppressive therapy was switched to the mTOR-inhibitor everolimus. A few months before, due to a progressive decline in renal function. Primarily, a community-acquired pneumonia was suspected and an empiric antibiotic therapy was initiated. Despite antimicrobial treatment, an acute respiratory distress syndrome developed and mechanical ventilation became necessary.
During the following extensive diagnostic a transbronchial lung biopsy was performed and histological analysis revealed a drug induced lung injury.
Based on the clinical and histological findings an everolimus induced pneumonitis was suspected.
The drug was immediately discontinued and a high-dose steroid treatment was started, resulting in a significant improvement of respiratory function.
Everolimus-related interstitial pneumonitis represents a rare but important adverse effect of everolimus in immunosuppressed patients. Recognition of everolimus induced pneumonitis is of high clinical relevance and should be considered in all patients on everolimus presenting with respiratory symptoms of unknown origin.
一名72岁的心脏移植受者因进行性呼吸困难入院。他的免疫抑制治疗改为使用mTOR抑制剂依维莫司。几个月前,由于肾功能逐渐下降。最初怀疑是社区获得性肺炎,并开始了经验性抗生素治疗。尽管进行了抗菌治疗,但仍发展为急性呼吸窘迫综合征,需要机械通气。
在接下来的广泛诊断过程中,进行了经支气管肺活检,组织学分析显示为药物性肺损伤。
根据临床和组织学检查结果,怀疑为依维莫司诱发的肺炎。
立即停用该药物,并开始大剂量类固醇治疗,呼吸功能得到显著改善。
依维莫司相关的间质性肺炎是依维莫司在免疫抑制患者中罕见但重要的不良反应。认识依维莫司诱发的肺炎具有高度临床相关性,对于所有出现不明原因呼吸道症状的依维莫司使用者均应考虑。